$306.50
3.441.14%
Last update: Nov 10, 4:00 PM
Krystal Biotech Inc
KRYSNASDAQ
Krystal Biotech rose 49.3% from $203.00 to $303.06, ahead of the S&P 500's +9.8%. Its worst day was Nov 2 (−11.0%), and its low came Nov 13 at $201.21.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Krystal Biotech closed at its lowest level of the year, 0.9% below where the year started.
−0.9% · S&P 500 −1.7%
Krystal Biotech shares rose 7.3%, while the S&P 500 fell 0.2%.
+7.3% · S&P 500 −0.2%
Story events cover the past 12 months · Times ET
EPS of $1.70 beat the $1.61 estimate on $107.1M revenue (est. $106.5M).
+4.1% · S&P 500 +0.2%
EPS of $1.83 beat the $1.43 estimate on $116.4M revenue (est. $112.1M).
+7.9%, the year's best day · S&P 500 −0.4%
Krystal Biotech closed at its highest level of the year, 86.3% above where the year started.
+1.6% · S&P 500 +1.6%
Krystal Biotech shares fell 6.6%, while the S&P 500 rose 0.4%.
−6.6% · S&P 500 +0.4%
EPS of $1.79 missed the $1.89 estimate on $119.2M revenue (est. $122.8M).
−8.4% · S&P 500 +1.4%
EPS of $2.05 beat the $1.90 estimate on $127.3M revenue (est. $126.2M).
−11.0%, the year's worst day · S&P 500 −0.5%
Where it ended: a close of $303.06 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 16, 2027 (EPS est. $2.09, revenue est. $138.2M).
Nothing in the past 12 months.
All KRYS dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KRYS and SPY from Benzinga historical bars. Not investment advice.
